Sinopharm Archives - Medical Design Sourcing

Elekta forms radiotherapy partnership with Sinopharm in China

Elekta announced today that it entered into a joint venture with Sinopharm to increase the adoption of radiation therapy in China.

The initiative aims to bring radiation therapy to what’s considered lower-tier cities. These cities comprise approximately 70% of China’s population, according to a news release.

Elekta develops precision radiation therapy to treat cancer. The FDA cleared its latest offering, the Comprehensive Motion Management (CMM) with True Tracking and automatic gating, last month.

Shanghai-based Sinopharm (China National Pharmaceutical Group) covers all aspects of healthcare. Its pharmaceutical business is the second largest in the world, according to our sister publication Drug Discovery & Development‘s Pharma 50 report. In addition to drug development, Sinopharm operates a substantial China-based logistics network for drugs and medical devices. It engages in R&D, manufacturing, logistics, distribution and healthcare…

GE HealthCare is expanding its partnership with Sinopharm in China

GE HealthCare (Nasdaq:GEHC) is forming a long-term joint venture with Sinopharm as it seeks to make additional inroads in China’s medical device market.

Shanghai-based Sinopharm is one of the largest life science products companies in the world. Its pharmaceutical business alone — with roughly $60 billion in annual revenue — places it at No. 2 in our sister publication Drug Discovery & Development‘s Pharma 50 report of the world’s largest pharma companies. In addition to drug development, Sinopharm operates a substantial China-based logistics network for drugs and medical devices.

Meanwhile, GE HealthCare is No. 6 in Medical Design & Outsourcing’s Medtech Big 100 report of the largest medical device companies.

In an SEC filing from Feb. 24, GE HealthCare said it has an existing joint venture relationship with Sinopharm that it made through Hangwei, a medical equipment manufacturing company formed in 1991. The new long-term…

China begins administering COVID-19 vaccines to children as young as 3

In China, roughly 80% of the population is vaccinated against COVID-19.

The country, along with Cuba, is also among the first to begin vaccinating young children. At least five out of 23 provinces have started administering shots to children aged three to 11.

China plans on hosting the 2022 Winter Olympics from February 4–20, 2022, in Beijing and the surrounding Hebei.

China is not allowing foreign spectators to attend the event.

The International Olympic Committee is also requiring that athletes, team staff and journalists who travel to Beijing for the Olympics be fully vaccinated or face a 21-day quarantine. In addition, attendees will also undergo mandatory daily PCR testing.

China has authorized vaccines from Sinopharm (HKG:1099) and Sinovac for children as young as three, but, to date, it has only vaccinated children 12 and up until recently.

In the West, the U.S. and several countries in Europe have authorized COVID-19 vaccines…

Sinopharm publishes COVID-19 vaccine trial data

An article recently published in JAMA concluded that two inactivated COVID-19 vaccines from Sinopharm (OTCMKTS: SHTDY) were 72.8% and 78.1% effective, respectively, based on interim Phase 3 study results.

The lower figure refers to the protection from a COVID-19 vaccine based on two 5-µg doses based on the SARS-CoV-2 isolate WIV04 complete genome. The second vaccine in the study was based on two 4-µg vaccine doses developed with the HB02 strain of SARS-CoV-2. Some 13,459 received the WIV04-based vaccine, while 13,465 received the HBO2 version.

A placebo group including 13,465 participants received aluminum hydroxide, a common adjuvant.

In all, the study involved 40,380 participants. Most participants in the study were relatively young men.

Sinopharm recruited study participants in the United Arab Emirates, Egypt, Jordan and Bahrain. The study population consisted of adults at least 18 years of age who believed they had not contracted COVID-19 o…

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies also overcame COVID-19-related clinical trial disruption and staffing hurdles, driving unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

One of the most notable achievements involved the mRNA vaccines from Pfizer/BioNTech and Moderna, according to analyst Mani Foroohar at SVB Leerink.

Other achievements, according to Foroohar, includ…

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.